Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | BCL9 | O00512 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL5476146 | 0.88 | BCL9 (0.58) | HTR2ABCL9CTNNB1GAATSHR | |
| SCHEMBL26374 | 0.88 | GAA (0.65) | HTR2ABCL9CTNNB1GAAPKM | |
| SCHEMBL7757606 | 0.87 | HTR2A (0.55) | HTR2ABCL9CTNNB1GAATSHR | |
| Alcohol SCHEMBL20595561 | 0.86 | BCL9 (0.66) | HTR2ABCL9CTNNB1GAATSHR | |
| SCHEMBL22398685 | 0.86 | KMT2A (0.68) | BCL9CTNNB1GAAMAOBPKM | |
| Hydrochloric Acid SCHEMBL7895043 | 0.86 | GAA (0.62) | HTR2ABCL9CTNNB1GAAPKM | |
| SCHEMBL15604223 | 0.85 | BCL9 (0.60) | HTR2ABCL9CTNNB1GAATSHR | |
| SCHEMBL4598350 | 0.84 | HSPB1 (0.59) | TSHRMAOBKMT2AIDO1LOXL2 | |
| Paranitrobenzyl Alcohol SCHEMBL114620 | 0.84 | TSHR (0.69) | TSHRIDO1LOXL2ALDH1A1 | |
| SCHEMBL1394964 | 0.84 | PPARG (0.50) | TSHRKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20170128580-A1 | TARGETED THERAPEUTICS | TARVEDA THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9597343-B2 | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170049899-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2017-02-23 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| EP-2709668-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | Koninklijke Philips N.V. (NL) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012156920-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-11-22 | — | — | WO | disclosed |
| US-20120142718-A1 | N-17-Alkylated Prodrugs of Opioids | SIGNATURE THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142718-A1 | N-17-Alkylated Prodrugs of Opioids | SIGNATURE THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142718-A1 | N-17-Alkylated Prodrugs of Opioids | SIGNATURE THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2008101202-A1 | N-17-ALKYLATED PRODRUGS OF OPIOIDS | PHARMACOFORE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008101202-A1 | N-17-ALKYLATED PRODRUGS OF OPIOIDS | PHARMACOFORE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20060269480-A1 | Multi-triggered self-immolative dendritic compounds | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128580-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HTR2A 3907/4885BCL9 1131/4885CTNNB1 3817/4885 |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | HTR2A 1007/4885BCL9 3102/4885CTNNB1 1687/4885 |
| US-20170049899-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HTR2A 3907/4885BCL9 1131/4885CTNNB1 3817/4885 |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | HTR2A 3074/4885BCL9 466/4885CTNNB1 1429/4885 |
| US-20120142718-A1 | N-17-Alkylated Prodrugs of Opioids | OPRM1, OPRD1, OPRL1 | HTR2A 204/4885BCL9 4360/4885CTNNB1 2790/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HTR2A 3907/4885BCL9 1131/4885CTNNB1 3817/4885 |
| US-20060269480-A1 | Multi-triggered self-immolative dendritic compounds | CD14, DCLK1, ADAM9 | HTR2A 4497/4885BCL9 673/4885CTNNB1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.